Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL29824737 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL6332969 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL263201 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL9474227 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL8467361 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL11054858 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL263200 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL191753 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL7804046 | 0.97 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL4953538 | 0.97 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461006-B1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLUORIDE | PROCTER & GAMBLE (US) | 2016-09-28 | — | — | EP | claimed |
| CN-100386065-C | Stable oral compositions comprising casein phosphopeptide complexes and flouride | PROCTER & GAMBLE (US) | 2008-05-07 | — | — | CN | claimed |
| CN-1610535-A | Stable oral compositions comprising casein phosphopeptide complexes and flouride | PROCTER & GAMBLE (US) | 2005-04-27 | — | — | CN | claimed |
| US-6863882-B2 | Stable oral compositions comprising casein phosphopeptide complexes and fluoride | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-08 | — | — | US | claimed |
| EP-1461006-A1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLOURIDE | The Procter & Gamble Company (US) | 2004-09-29 | — | — | EP | claimed |
| WO-2003059304-A1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLOURIDE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| US-20030124066-A1 | Stable oral compositions comprising casein phosphopeptide complexes and fluoride | PROCTER AND GAMBLE COMPANY, THE | 2003-07-03 | — | — | US | claimed |
| CN-108289928-B | Improved microorganism-binding molecules and uses thereof | 哈佛大学校长及研究员协会 | 2024-09-17 | — | — | CN | disclosed |
| WO-2022215619-A1 | COMPOSITION FOR PROMOTING GLP-1 SECRETION | 株式会社林原 | 2022-10-13 | — | — | WO | disclosed |
| CN-114929271-A | Nanoemulsion compositions for the treatment of aeroallergen-related allergies and inflammation | 密歇根大学董事会 | 2022-08-19 | — | — | CN | disclosed |
| CN-112789350-A | Antimicrobial sensitivity testing using microdroplets | 贝克顿·迪金森公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-1461006-B1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLUORIDE | PROCTER & GAMBLE (US) | 2016-09-28 | — | — | EP | disclosed |
| CN-104093421-A | Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine | NANOBIO CORP | 2014-10-08 | — | — | CN | disclosed |
| US-20050143274-A1 | Compositions and methods of delivering bleaching agents to teeth | PROCTER & GAMBLE COMPANY, THE | 2005-06-30 | — | — | US | disclosed |
| US-20050137110-A1 | Compositions and methods of delivering bleaching agents to teeth | THE PROCTOR & GAMBLE COMPANY | 2005-06-23 | — | — | US | disclosed |
| CN-1610535-A | Stable oral compositions comprising casein phosphopeptide complexes and flouride | PROCTER & GAMBLE (US) | 2005-04-27 | — | — | CN | disclosed |
| US-6863882-B2 | Stable oral compositions comprising casein phosphopeptide complexes and fluoride | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1461006-A1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLOURIDE | The Procter & Gamble Company (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003059304-A1 | STABLE ORAL COMPOSITIONS COMPRISING CASEIN PHOSPHOPEPTIDE COMPLEXES AND FLOURIDE | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030124066-A1 | Stable oral compositions comprising casein phosphopeptide complexes and fluoride | PROCTER AND GAMBLE COMPANY, THE | 2003-07-03 | — | — | US | disclosed |